Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Bellerophon Therapeutics, Inc. (BLPH)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.0300-0.0800 (-7.21%)
At close: 04:00PM EDT
1.0000 -0.03 (-2.91%)
After hours: 06:02PM EDT
Advertisement

Bellerophon Therapeutics, Inc.

184 Liberty Corner Road
Suite 302
Warren, NJ 07059
United States
908 574 4770
https://bellerophon.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees20

Key Executives

NameTitlePayExercisedYear Born
Mr. Peter Fernandes M. PharmPrincipal Exec. Officer and Chief Regulatory, Safety & Quality Officer478.84kN/A1955
Dr. Parag Suresh ShahVP of Bus. Operations377.9kN/A1977
Mr. Nicholas LacconaPrincipal Financial & Accounting Officer and Sec.N/AN/A1989
Dr. Edwin L. ParsleyActing Chief Medical OfficerN/AN/A1961
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Corporate Governance

Bellerophon Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement